Related Experiment Video
Updated: Jul 9, 2026

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains
Published on: January 5, 2016
Polyunsaturated fatty acids induce alpha-synuclein-related pathogenic changes in neuronal cells
Karen Assayag1, Evgenia Yakunin, Virginie Loeb
1Department of Cellular Biochemistry and Human Genetics, Hebrew University, Hadassah Medical School, Jerusalem, Israel.
Abstract:
The misfolding and aggregation of normally soluble proteins has emerged as a key feature of several neurodegenerative diseases. In Parkinson's disease, progressive loss of dopaminergic neurons is accompanied by polymerization of the cytoplasmic protein alpha-synuclein (alphaS) into filamentous inclusions found in neuronal somata (Lewy bodies) and dendrites (Lewy neurites). Similar alphaS aggregates occur in cortical neurons in dementia with Lewy bodies. Numerous reports now indicate that alphaS can interact with lipids. We previously found that treating dopaminergic cells expressing alphaS with polyunsaturated fatty acids (PUFAs) induced the formation of soluble, sodium dodecyl sulfate-stable oligomers whereas treatment with saturated fatty acids did not. Here, we examine the relevance of alphaS-PUFA interactions to the development of Parkinson's disease-like cytopathology. Exposure of alphaS-overexpressing dopaminergic or neuronal cell lines to physiological levels of a PUFA induced the formation of proteinaceous inclusions in the cytoplasm. Kinetic experiments indicated that PUFA-induced soluble oligomers of alphaS precede these Lewy-like inclusions. Importantly, we found that alphaS oligomers were associated with cyto-toxicity, whereas the development of Lewy-like inclusions appeared to be protective. We conclude that alterations in PUFA levels can lead to aggregation of alphaS and subsequent deposition into potentially cyto-toxic oligomers that precede inclusions in dopaminergic cells.
Related Concept Videos
Parkinson Disease ll: Pathophysiology
Neural Regulation
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer Disease ll: Pathophysiology
Alzheimer Disease l: Introduction

